Long-term value

Our value creation

We are building on our solid fundamentals to create long-term value for our stakeholders as a sustainable business partner and a good corporate citizen, using science and innovation to help deliver better health.

Economic value

  • Dividends: €3.9bn paid out to our shareholders1
  • Proposed dividend of €3.20 per share to be submitted for approval to the 2021 Annual General Meeting, the 27th consecutive year in which we have increased our dividend
  • Suppliers: €14.8bn Sanofi spend
  • Income tax and other taxes paid: €2.4bn

Health value

  • Pharmaceutical contributions paid to healthcare systems: €5.7bn
  • Addressing public health needs:
    – Healthcare access programs: 124 million patients reached via 23 programs in 117 countries
    – Over half a billion people vaccinated worldwide in 2020
    – Medicines and healthcare solutions available in more than 170 countries
  • Education for better health: 260,000 healthcare professionals trained
  • Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030

Scientific value

  • Accelerate R&D focus on six potentially transformative medicines in the areas of breast cancer, hemophilia, multiple rare diseases, respiratory syncytial virus and multiple sclerosis:
    – Amcenestrant
    – Fitusiran
    – Efanesoctocog alpha2
    – Venglustat
    – Nirsevimab3
    – Tolebrutinib
  • 40 projects in phase 3 or submitted to regulatory authorities for approval
  • 83 projects in clinical development including 32 new molecular entities

Social value

  • Personnel costs: €9bn
  • 5.3% of work-study contracts awarded to young people from priority neighborhoods under the PAQTE initiative, the French government’s urban renewal policy
  • Gender parity ambition 2025: gender parity among Sanofi senior leaders
  • Mobilizing for the planet:
    Reduction of 22% in water consumption since 2015
    Reduction of 27% of CO2 emissions since 2015

1 2019 dividends paid in 2020.
2 In partnership with Swedish Orphan Biovitrum (Sobi).
3 In partnership with AstraZeneca.
All data: 2020 unless otherwise indicated.